Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ani Pharmaceuticals (ANIP) Cost of Revenue: 2012-2025

Historic Cost of Revenue for Ani Pharmaceuticals (ANIP) over the last 14 years, with Sep 2025 value amounting to $93.4 million.

  • Ani Pharmaceuticals' Cost of Revenue rose 48.06% to $93.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $321.3 million, marking a year-over-year increase of 43.86%. This contributed to the annual value of $250.2 million for FY2024, which is 37.85% up from last year.
  • According to the latest figures from Q3 2025, Ani Pharmaceuticals' Cost of Revenue is $93.4 million, which was up 25.16% from $74.6 million recorded in Q2 2025.
  • Ani Pharmaceuticals' 5-year Cost of Revenue high stood at $93.4 million for Q3 2025, and its period low was $20.0 million during Q1 2021.
  • For the 3-year period, Ani Pharmaceuticals' Cost of Revenue averaged around $61.2 million, with its median value being $57.7 million (2024).
  • Per our database at Business Quant, Ani Pharmaceuticals' Cost of Revenue fell by 8.34% in 2021 and then surged by 71.48% in 2022.
  • Over the past 5 years, Ani Pharmaceuticals' Cost of Revenue (Quarterly) stood at $33.9 million in 2021, then rose by 7.16% to $36.3 million in 2022, then soared by 47.06% to $53.4 million in 2023, then spiked by 50.28% to $80.3 million in 2024, then spiked by 48.06% to $93.4 million in 2025.
  • Its Cost of Revenue stands at $93.4 million for Q3 2025, versus $74.6 million for Q2 2025 and $73.0 million for Q1 2025.